Abstract:Croton cajucara Benth showed several pharmacological properties such as: antiinflammatory,
antinociceptive hypoglycemic, lipid-lowering, antiulcer, antiestrogenic, antitumor, antigenotoxic,
antimutagenic, and cardiovascular. The 19-nor-clerodane diterpene transdehydrocrotonin
(t-DCTN or DCTN) is the major bioactive constituent extracted from the bark of this
Croton. Patents for Croton cajucara Benth in the period 2015 to 2022 comprises 14 published documents.
Among them 4 patents are colloidal systems (SM/SNEDDS) loading t-DCTN for pharmacological
applications. Patent registrations highlighted the huge promising biotechnological potential of
Croton cajucara Benth especially in the phytotherapy field, and the correlation with its bioactive constituents
of which t-DCTN showed the foremost results, so this herbal could become an alternative in
the treatment of COVID-19. However, investigation of more recently published patents for clerodane
diterpenes with similar chemical structure of t-DCTN, who previously showed antiviral property must
be carried out and should be searched on several patent data bases.